This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Joseph Roscoe, University of Rochester
ClinicalTrials.gov Identifier:
NCT01091974
First received: December 9, 2009
Last updated: December 16, 2016
Last verified: December 2016
Results First Received: February 5, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Supportive Care
Conditions: Insomnia
Fatigue
Breast Cancer
Interventions: Drug: armodafinil
Drug: Placebo Comparator
Behavioral: CBT-I

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
138 Patients were consented of which 114 were eligible.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
18 Withdrew prior to randomization (3 ceased responding to contacts, 4 changed mind , 3 began or restarted sleep medication, 4 did not complete baseline measures, 1 did not receive approval from physician to participate, 1 found the diaries too much trouble, 1 did not want to take study medication, and 1 had a family emergency).

Reporting Groups
  Description
Arm 1 - (CBT-I) + Placebo

Placebo Comparator: Placebo for 47 days

CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)

2 - CBT-I + Armodafinil

Armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)

CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)

3- Placebo Only Placebo Comparator: Placebo for 47 days
4 - Armodafinil Only Armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)

Participant Flow:   Overall Study
    Arm 1 - (CBT-I) + Placebo   2 - CBT-I + Armodafinil   3- Placebo Only   4 - Armodafinil Only
STARTED   24   23   25   24 
COMPLETED   19   18   19   17 
NOT COMPLETED   5   5   6   7 
Did not start intervention                3                1                3                1 
resumed sleep medication                0                0                1                2 
Withdrawal by Subject                1                3                2                2 
side-effects                1                1                0                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
1 - CBT-I + Placebo

CBT-I and placebo

Placebo Comparator: Placebo for 47 days

CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)

2 - CBT-I + Armodafinil

CBT-I + Armodafinil

armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)

CBT-I: Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)

3 - Placebo Only

Placebo only

Placebo Comparator: Placebo for 47 days

4 - Armodafinil Only

Armodafinil only

armodafinil: Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)

Total Total of all reporting groups

Baseline Measures
   1 - CBT-I + Placebo   2 - CBT-I + Armodafinil   3 - Placebo Only   4 - Armodafinil Only   Total 
Overall Participants Analyzed 
[Units: Participants]
 24   23   25   24   96 
Age 
[Units: Years]
Mean (Standard Deviation)
 59  (9.9)   56  (10.2)   52  (11.5)   57  (7.4)   56.1  (10.0) 
Gender 
[Units: Participants]
Count of Participants
         
Female      21  87.5%      22  95.7%      18  72.0%      23  95.8%      84  87.5% 
Male      3  12.5%      1   4.3%      7  28.0%      1   4.2%      12  12.5% 
Ethnicity (NIH/OMB) 
[Units: Participants]
Count of Participants
         
Hispanic or Latino      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Not Hispanic or Latino      23  95.8%      22  95.7%      24  96.0%      22  91.7%      91  94.8% 
Unknown or Not Reported      1   4.2%      1   4.3%      1   4.0%      2   8.3%      5   5.2% 
Race (NIH/OMB) 
[Units: Participants]
Count of Participants
         
American Indian or Alaska Native      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Asian      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Native Hawaiian or Other Pacific Islander      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Black or African American      1   4.2%      2   8.7%      4  16.0%      1   4.2%      8   8.3% 
White      23  95.8%      21  91.3%      19  76.0%      23  95.8%      86  89.6% 
More than one race      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Unknown or Not Reported      0   0.0%      0   0.0%      2   8.0%      0   0.0%      2   2.1% 
Region of Enrollment 
[Units: Participants]
         
United States   24   23   25   24   96 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Insomnia Severity Index From Baseline to Post-intervention   [ Time Frame: ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre). ]

2.  Secondary:   Fatigue Will be Assessed by the Total Score of the Revised Brief Fatigue Inventory (BFI) .   [ Time Frame: ANCOVA was employed with multiple imputation on the post-intervention score (average of the two post-intervention weeks), controlling for the score at the time of consent (pre). ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Joseph A. Roscoe Ph.D.
Organization: University of Rochester Medical Center
phone: (585) 275-9962
e-mail: Joseph_Roscoe@URMC.Rochester.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Joseph Roscoe, University of Rochester
ClinicalTrials.gov Identifier: NCT01091974     History of Changes
Other Study ID Numbers: UCCS07090
1R01CA126968-01A1 ( U.S. NIH Grant/Contract )
Study First Received: December 9, 2009
Results First Received: February 5, 2015
Last Updated: December 16, 2016